NCT05213195View on ClinicalTrials.gov

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Refractory Metastatic Colorectal Cancer
Interventions
DRUG

NKG2D CAR-NK

NKG2D CAR-NK infusion through peritoneal in stage 1 and later combined with intra venous in stage 2.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER